Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies
Abstract
Although enzalutamide (ENZ) has been widely used to treat de novo or castration-resistant metastatic prostate cancer, resistance develops and disease progression is ultimately inevitable. There are currently no approved targeted drugs to specifically delay or overcome ENZ resistance.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 04, 2021
- Source ID
- 10.1158/1078-0432.ccr-20-3260
Entities
People
- Adam Sharp
- Aleksandra Pesic
- Amanda Mawson
- Amina Zoubeidi
- Anthony M Joshua
- Antje Neeb
- Bora Gurel
- Bradly Wouters
- Bruce Montgomery
- David Uehling
- Haiyang Guo
- Housheng Hansen He
- Ines Figueiredo
- Joan Sweet
- Johann de Bono
- Marianne Koritzinsky
- Martin Gleave
- Richard Marcellus
- Samantha R Oakes
- Stefano Marastoni
- Sujeeve Jeganathan
- Yi Liang
- Zvi Shalev
Organizations
- Academy of Medical Sciences
- Medical Research Council
- Ontario Institute for Cancer Research
- Sanofi Pasteur
- University Health Network
- University of British Columbia
- University of New South Wales
- University of Toronto
- University of Washington